2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

112. Thalassemia and Globin Gene Regulation: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Biological Therapies, Transfusion, Women’s Health, Biological Processes, Multi-Systemic Interactions, Diseases, Hemoglobinopathies, Thalassemia, Metabolic Disorders, Iron Overload, Research, Clinical Research, Clinical Trials, Epidemiology, Study Population, Human, Adult, Animal Model
PAPER

4654 Maternal iron overload and anemia increase the risk of pre-eclampsia, peripartum cardiomyopathy, and adverse fetal and postnatal offspring outcomes in a mouse model of β-thalassemia pregnancy

Lucia Lee, Veena Sangkhae, PhD2, Sitara Sriram3, Tomas Ganz, MD, PhD4, James F Collins, PhD5, Elizabeth Nemeth, PhD6
1 David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States
2 David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States
3 University of Florida, Gainesville, Florida, United States
4 David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States
5 University of Florida, Gainesville, Florida, United States
6 David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States

In β-thalassemia, anemia and ineffective erythropoiesis suppress the hepatic hormone hepcidin, leading to systemic iron overload—a primary driver of patient morbidity and mortality. Recent improvements in transfusion and chelation therapies now allow more women with the condition to have successful pregnancies. However, thalassemic pregnancies are associated with an increased risk for intrauterine growth restriction, preterm birth, and other complications such as pre-eclampsia for reasons that are not well understood. Mitigating iron loading during pregnancy presents a challenge since transfusion rates increase while chelation is suspended to protect the fetus from teratogenic effects.  


We used the Th3/+ β-thalassemia mouse model to examine the effect of maternal thalassemia on pregnancy and offspring outcomes at E18.5 of gestation and postnatally. Th3/+ dams carried fetuses of both genotypes (WT or Th3). Control pregnancies were WT C57BL/6 dams carrying WT fetuses. Iron-deficiency anemia (IDA) dams fed a low Fe diet (4-ppm Fe) were studied in parallel to understand the effect of anemia without iron loading, while Hamp KO dams were used to elucidate the effect of iron loading without anemia. 


Th3/+ dams were iron overloaded (due to inappropriately low hepcidin) and anemic, with cardiomegaly, hepatomegaly, and multi-organ dysfunction. Notably, we observed increased blood pressure and expression of several pre-eclampsia biomarkers in maternal serum and placenta solely in Th3/+ dams, which is consistent with the increased risk for pre-eclampsia that has been documented in pregnant thalassemic women. We observed in dams high mortality and persistent post-weaning peripartum cardiomyopathy characterized by abnormal myosin heavy chain remodeling. Neither IDA nor Hamp KO dams had persistent cardiomyopathy or features of pre-eclampsia, indicating that β-Thalassemia dams have a unique susceptibility to adverse pregnancy outcomes, likely resulting from the combination of severe anemia and iron overload.


Compared to WT pregnancies, fetuses from Th3/+ dams were growth restricted and iron loaded, with oxidative stress and hypoxia in multiple tissues. Notably, abnormalities in thalassemic pregnancies were seen even in WT fetuses from Th3/+ dams, indicating a strong effect of maternal disease on fetal health. In the fetal brain from thalassemic pregnancies, we detected higher iron loading, increased expression of oxidative stress biomarkers and a 4-fold decrease in DNA methylation, regardless of fetal genotype. Strikingly, fetal brains from iron-overloaded Hamp KO dams also exhibited global hypomethylation, whereas those from iron-deficient dams did not—demonstrating that excess iron, rather than anemia, drives DNA hypomethylation during fetal brain development. Hypomethylation in the brain persisted into adulthood. We observed delays in developmental milestones in adult WT female offspring from Th3/+ dams including delayed eye-opening, and deficits on several behavioral tests.


Our findings align with clinical data demonstrating that β-thalassemia pregnancies carry a heightened risk of severe maternal and neonatal complications. Clinical studies are needed to ascertain if human pregnancies and fetuses are similarly affected by maternal β-thalassemia. Overall, our findings provide strong impetus to re-examine clinical management protocols for women with β-thalassemia before, during, and after pregnancy to better understand maternal-fetal risk and improve clinical outcomes for mother and offspring.

Lucia Lee: No relevant conflicts of interest to declare.